Home › Blood Cancers › North Carolina
Blood Cancers clinical trials in North Carolina
24 studies for Blood Cancers are looking for participants at sites in North Carolina.
Cities in North Carolina
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- WakeMed Cancer Care - Waverly Hematology & Medical Oncology ( Site 0074), Cary
- University of North Carolina at Chapel Hill ( Site 0040), Chapel Hill
- Duke Cancer Center ( Site 0028), Durham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT03486873Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- and 6 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 27, Chapel Hill
RecruitingPhase 3
Ages 18 to 71 · All sexes · Updated Sep 23, 2026 · NCT07504458Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Duke University, Durham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07648264Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Duke Cancer Center Cary, Cary
- Duke University Medical Center, Durham
- East Carolina University, Greenville
- and 5 more
RecruitingObservational study
All ages · All sexes · Updated Sep 17, 2026 · NCT04242095Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- UNC School of Medicine, Division of Hematology, Chapel Hill
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 3, 2026 · NCT04588922A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- Novant Health Weisiger Cancer Institute, Charlotte
RecruitingObservational study
Ages 0 and older · All sexes · Updated Sep 2, 2026 · NCT07154823Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of North Carolina, Chapel Hill, Chapel Hill
- Duke University Medical Center, Durham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Atrium Health Levine Cancer Center, Charlotte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06001788DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill
Recruiting
Ages 60 and older · All sexes · Updated Aug 14, 2026 · NCT06296368A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
- Levine Cancer Institute, Charlotte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06823167PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
- Lineberger Cancer, Chapel Hill
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT06665100ONC-MM-2407: The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period
- Levine Cancer Insitute, Charlotte
Recruiting
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT07203534Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment
- 2400 Pratt Street, Durham
Recruiting
Ages 18 and older · All sexes · Updated Jul 8, 2026 · NCT06532773Implementation of an Oral Chemotherapy Adherence Intervention
- UNC Chapel Hill, Chapel Hill
Recruiting
Ages 21 and older · All sexes · Updated Jul 8, 2026 · NCT06989489A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of North Carolina at Chapel Hill, Chapel Hill
- Levine Children's Hospital, Charlotte
- Duke University Medical Center, Durham
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545Optimizing Health Related Quality of Life Measurement in Adolescent and Young Adult Oncology
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RecruitingObservational studyHealthy volunteers welcome
Ages 15 and older · All sexes · Updated Jun 30, 2026 · NCT06897137Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of North Carolina, Chapel Hill
RecruitingPhase 1
Ages 13 and older · All sexes · Updated May 5, 2026 · NCT04771572CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Duke University Medical Center, Duke Cancer Center, Durham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT03328078A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Duke Blood Cancer Center, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT05735184HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT
- Duke University Health System, Durham
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Jan 16, 2026 · NCT06731504A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
- Levine Cancer Institute, Charlotte
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 25, 2025 · NCT05768269IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Atrium Health Wake Forest Baptist, Winston-Salem
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 3, 2025 · NCT06119685Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Carolina-Levine Children's Hospital, Charlotte
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Dec 6, 2024 · NCT05476770From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.